The above noted findings created a therapeutic dilemma. The patients who might benefit the most from the maintenance of sinus rhythm (atrial fibrillation and CHF) may also be at the highest risk.
Canadian pharmacy
Amiodarone is a unique antiarrhythmic agent originally developed as an antianginal agent. Although classified as a type III agent, amiodarone also has sodium and calcium channel, and beta receptor blocking properties. Studies have shown the maintenance of sinus rhythm in up to 70% of patients, including those who have failed other antiarrhythmic agents. In addition, amiodarone does not have the same proarrhythmic potential as other agents. In fact it may offer protection against sudden death in patients with heart failure. Although clearly the most efficacious antiarrhythmic available for the treatment of both atrial and ventricular arrhythmias, amiodarone therapy is associated with significant toxicities (pulmonary, thyroid, hepatic, neurologic, ophthalmologic). These toxicities appear to be somewhat does related, and the incidence is less on the standard atrial fibrillation dose of 200 mg/day.